These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11728215)

  • 21. The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori.
    Chui SY; Clay TM; Lyerly HK; Morse MA
    Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):1883-9. PubMed ID: 16103431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent developments in Helicobacter pylori vaccination.
    Kusters JG
    Scand J Gastroenterol Suppl; 2001; (234):15-21. PubMed ID: 11768556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination and mucosal responses to Helicobacter pylori infection.
    Lee A; Buck F
    Aliment Pharmacol Ther; 1996 Apr; 10 Suppl 1():129-38. PubMed ID: 8730267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventive and therapeutic vaccines against Helicobacter pylori: current status and future challenges.
    Ernst PB; Pappo J
    Curr Pharm Des; 2000 Oct; 6(15):1557-73. PubMed ID: 10974152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progress in vaccine development against Helicobacter pylori.
    Svennerholm AM; Lundgren A
    FEMS Immunol Med Microbiol; 2007 Jul; 50(2):146-56. PubMed ID: 17442014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspectives of anti-H. pylori vaccination.
    Saldinger PF; Blum AL; Corthésy-Theulaz IE
    J Physiol Pharmacol; 1997 Sep; 48 Suppl 4():59-65. PubMed ID: 9440056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammation, immunity, vaccines for Helicobacter pylori infection.
    Koch M; Meyer TF; Moss SF
    Helicobacter; 2013 Sep; 18 Suppl 1():18-23. PubMed ID: 24011240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammation, immunity, and vaccines for Helicobacter pylori infection.
    Ihan A; Pinchuk IV; Beswick EJ
    Helicobacter; 2012 Sep; 17 Suppl 1(Suppl 1):16-21. PubMed ID: 22958150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunology and vaccines and nanovaccines for Helicobacter pylori infection.
    Milani M; Sharifi Y; Rahmati-Yamchi M; Somi MH; Akbarzadeh A
    Expert Rev Vaccines; 2015 Jun; 14(6):833-40. PubMed ID: 25645086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity characterization of the multi-epitope vaccine CTB-UE with chitosan-CpG as combination adjuvants against Helicobacter pylori.
    Xing Y; Liu W; Li X; Guo L; Lv X; Xi T
    Biochem Biophys Res Commun; 2015 Jul; 462(3):269-74. PubMed ID: 25957472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of oral vaccination with Lactococcus lactis derived vaccine candidate antigen (UreB) of Helicobacter pylori fused with the human interleukin 2 as adjuvant.
    Zhang HX; Qiu YY; Zhao YH; Liu XT; Liu M; Yu AL
    Mol Cell Probes; 2014 Feb; 28(1):25-30. PubMed ID: 24036137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Helicobacter pylori vaccine development: optimisation of strategies and importance of challenging strain and animal model.
    Hoffelner H; Rieder G; Haas R
    Int J Med Microbiol; 2008 Jan; 298(1-2):151-9. PubMed ID: 17714988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Helicobacter pylori and gastroduodenal disorders: new approaches for prevention, diagnosis and treatment.
    Kotloff KL
    Vaccine; 1996 Aug; 14(12):1174-5. PubMed ID: 8911016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A vaccine against Helicobacter pylori infection].
    Presecki V; Katicić M; Kalenić S; Strnad M; Plecko V; Babus V; Dominis M
    Lijec Vjesn; 2002 Sep; 124 Suppl 1():79-82. PubMed ID: 12592824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Helicobacter pylori infection, immune response and vaccination.
    Lembo A; Caradonna L; Magrone T; Mastronardi ML; Caccavo D; Jirillo E; Amati L
    Curr Drug Targets Immune Endocr Metabol Disord; 2001 Nov; 1(3):199-208. PubMed ID: 12477286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection.
    Shi T; Liu WZ; Gao F; Shi GY; Xiao SD
    Helicobacter; 2005 Feb; 10(1):71-9. PubMed ID: 15691317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Towards the development of vaccines against Helicobacter pylori: status and issues.
    Del Giudice G
    Curr Opin Investig Drugs; 2001 Jan; 2(1):40-4. PubMed ID: 11527009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic Helicobacter pylori immunization in mice.
    Nyström J; Raghavan S; Svennerholm AM
    Microbes Infect; 2006 Feb; 8(2):442-9. PubMed ID: 16243563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological response of recombinant H. pylori multi-epitope vaccine with different vaccination strategies.
    Wang B; Pan X; Wang H; Zhou Y; Zhu J; Yang J; Li W
    Int J Clin Exp Pathol; 2014; 7(10):6559-66. PubMed ID: 25400734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vaccination against H. pylori: an achievable goal].
    Ferrero RL
    Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 2):488-93. PubMed ID: 12700508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.